American Capital Advisory LLC Has $735,000 Stock Holdings in Sanofi (NASDAQ:SNY)

American Capital Advisory LLC lessened its holdings in Sanofi (NASDAQ:SNY) by 34.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,247 shares of the company’s stock after selling 8,134 shares during the quarter. American Capital Advisory LLC’s holdings in Sanofi were worth $735,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Apollon Wealth Management LLC grew its position in Sanofi by 8.8% during the fourth quarter. Apollon Wealth Management LLC now owns 17,865 shares of the company’s stock worth $862,000 after buying an additional 1,441 shares in the last quarter. Mezzasalma Advisors LLC increased its position in shares of Sanofi by 24.0% in the fourth quarter. Mezzasalma Advisors LLC now owns 12,686 shares of the company’s stock worth $612,000 after purchasing an additional 2,452 shares during the period. Strategic Financial Concepts LLC acquired a new position in Sanofi in the fourth quarter valued at about $667,000. Leo Wealth LLC lifted its position in Sanofi by 5.9% during the fourth quarter. Leo Wealth LLC now owns 26,669 shares of the company’s stock worth $1,286,000 after purchasing an additional 1,487 shares during the period. Finally, Yousif Capital Management LLC grew its stake in Sanofi by 53.2% during the fourth quarter. Yousif Capital Management LLC now owns 59,611 shares of the company’s stock worth $2,875,000 after buying an additional 20,690 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on SNY shares. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Performance

Sanofi stock opened at $53.35 on Friday. The business has a 50 day moving average of $49.72 and a 200-day moving average of $52.37. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a market capitalization of $135.39 billion, a P/E ratio of 21.43, a P/E/G ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. On average, equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.